Company intelligence / Profile preview
Pentixapharm
Würzburg, Germanypentixapharm.com ↗
- Ownership
- Public · PTPN
- Employees
- ~80
- Development stage
- Phase 3
01
Overview
Compounds administered to more than 2,000 patients; CXCR4 compound extensively studied in 150+ scientific papers; Two Phase-III-ready drug candidates; PentixaFor is in Phase III for marginal zone lymphoma; dose-finding study for PentixaTher is ongoing
- Therapeutic areas
- OncologyEndocrinologyCardiovascularImmunology
- Modalities
- RadiopharmaceuticalsCXCR4 ligand-based compounds
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Financials
- Market cap
- $2.2M
- Total revenue
- $5.1B
Beyond the preview
Go deeper on Pentixapharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentixapharm.